Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
102 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Acute Ischemic Stroke - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H2 2014', provides an overview of the Acute Ischemic Stroke's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Ischemic Stroke and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Acute Ischemic Stroke Overview 8 Therapeutics Development 9 Pipeline Products for Acute Ischemic Stroke - Overview 9 Pipeline Products for Acute Ischemic Stroke - Comparative Analysis 10 Acute Ischemic Stroke - Therapeutics under Development by Companies 11 Acute Ischemic Stroke - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Acute Ischemic Stroke - Products under Development by Companies 16 Acute Ischemic Stroke - Companies Involved in Therapeutics Development 17 Biogen Idec Inc. 17 AstraZeneca PLC 18 Daiichi Sankyo Company, Limited 19 Grifols, S.A. 20 Reliance Life Sciences Pvt. Ltd. 21 H. Lundbeck A/S 22 Mitsubishi Tanabe Pharma Corporation 23 Oxygen Biotherapeutics, Inc. 24 PhytoHealth Corporation 25 Simcere Pharmaceutical Group 26 D-Pharm Ltd. 27 Remedy Pharmaceuticals, Inc. 28 Stemedica Cell Technologies, Inc. 29 Glucox Biotech AB 30 Pharmicell Co., Ltd. 31 Genervon Biopharmaceuticals, LLC 32 Acute Ischemic Stroke - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 desmoteplase - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 ticagrelor - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Cerecellgram-Stroke - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 natalizumab - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 SIM-071201 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 GM-602 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 glyburide - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Mesenchymal Stem Cells - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 THR-18 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 3K3A-APC - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 PHN-014 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 RTPR-004 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Human Plasmin - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 MP-124 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 TS-01 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 DS-1040 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Oxycyte - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Recombinant Plasmin - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 HBN-1 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Human Ghrelin - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Acute Ischemic Stroke - Recent Pipeline Updates 75 Acute Ischemic Stroke - Dormant Projects 91 Acute Ischemic Stroke - Discontinued Products 92 Acute Ischemic Stroke - Product Development Milestones 93 Featured News & Press Releases 93 Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA 93 Jun 03, 2014: Thrasos Presents Preclinical Data Demonstrating THR-184 Prevents Loss of Kidney Function Following Acute Ischemic Injury 93 Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA 94 Apr 22, 2014: ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures 94 Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients 96 Jan 21, 2014: D-Pharm completes recruitment of patients into the first dosage tier of its Phase 2 study with THR-18 in acute stroke patients treated with tPA 96 Jan 08, 2014: D-Pharm receives grant to support the development of its Phase 2 product, THR-18 97 Dec 05, 2013: AstraZeneca announces initiation of two additional global studies for BRILINTA 97 Oct 30, 2013: D-Pharm Granted Patent in US and China for its Phase II Product THR-18 99 Oct 16, 2013: D-Pharm Commences Phase 2 Study with THR-18 In Stroke Patients Treated with Tissue Plasminogen Activator 99 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 102 Disclaimer 102
List of Tables Number of Products under Development for Acute Ischemic Stroke, H2 2014 9 Number of Products under Development for Acute Ischemic Stroke - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Acute Ischemic Stroke - Pipeline by Biogen Idec Inc., H2 2014 17 Acute Ischemic Stroke - Pipeline by AstraZeneca PLC, H2 2014 18 Acute Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 19 Acute Ischemic Stroke - Pipeline by Grifols, S.A., H2 2014 20 Acute Ischemic Stroke - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2014 21 Acute Ischemic Stroke - Pipeline by H. Lundbeck A/S, H2 2014 22 Acute Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 23 Acute Ischemic Stroke - Pipeline by Oxygen Biotherapeutics, Inc., H2 2014 24 Acute Ischemic Stroke - Pipeline by PhytoHealth Corporation, H2 2014 25 Acute Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2014 26 Acute Ischemic Stroke - Pipeline by D-Pharm Ltd., H2 2014 27 Acute Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2014 28 Acute Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2014 29 Acute Ischemic Stroke - Pipeline by Glucox Biotech AB, H2 2014 30 Acute Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H2 2014 31 Acute Ischemic Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2014 32 Assessment by Monotherapy Products, H2 2014 33 Number of Products by Stage and Target, H2 2014 35 Number of Products by Stage and Mechanism of Action, H2 2014 38 Number of Products by Stage and Route of Administration, H2 2014 40 Number of Products by Stage and Molecule Type, H2 2014 42 Acute Ischemic Stroke Therapeutics - Recent Pipeline Updates, H2 2014 75 Acute Ischemic Stroke - Dormant Projects, H2 2014 91 Acute Ischemic Stroke - Discontinued Products, H2 2014 92
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
